Year: 2016
Type: article
Study design: Observational Study
Abstract: patients (76%) who underwent TT showed stable disease (SD) or response (PR or CR) by at least 1 targeted agent.Median OS of these 33 patients was 22.4 months.OS was significantly longer in patients undergoing TT (22.5 months) than those not undergoing TT (5.6 months) (p¼0.0043).Furthermore, median OS of patients who experienced SD or response using TT was 34.5 months.Median OS of patients who had durable SD (>12 months) using a single targeted agent (n¼7) was 43.1 months.Disease control rate (DCR) of sunitinib in the first-line setting was 77.8% (CR, 1 patient; PR, 1; SD, 5; and PD, 2).DCR in the second-line setting was 62.5%.DCR of sorafenib was 50%, and 2/10 patients using sorafenib had durable SDs (20 and 24 months).DCR of axitinib was 50%, and 2/6 patients using axitinib had durable SDs (14 and 14 months).Few patients among those using temsirolimus (DCR, 54.5%) and everolimus (DCR, 50%) had SD of >8 months.CONCLUSIONS: A significant number of tumors diagnosed as PRCC in each institute was categorized into other histological types.Prognosis of patients with mPRCC appeared to be improved by the sequential use of TT.
Source: The Journal of Urology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2331580903